Bowel ulceration following tocilizumab administration in a COVID-19 patient

Tocilizumab, a monoclonal antibody against interleukin-6, has been used to treat cytokine release syndrome (CRS) in a subset of patients with severe COVID-19 disease. Acute ulcerative bowel disease has been only rarely documented in patients treated for rheumatological conditions. The gastrointestin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruce-Hickman, Damian, Sajeed, Shanaz Matthew, Pang, Yin Huei, Seow, Choon Sheong, Chen, Weihao, Gulati Kansal, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437943/
https://www.ncbi.nlm.nih.gov/pubmed/32816957
http://dx.doi.org/10.1136/bmjgast-2020-000484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437943/
https://www.ncbi.nlm.nih.gov/pubmed/32816957
http://dx.doi.org/10.1136/bmjgast-2020-000484

Ejemplares similares